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Drug abuse and brain disorders related to drug comsumption are public health problems 33 
with harmful individual and social consequences. The identification of therapeutic targets and 34 
precise pharmacological treatments to these neuropsychiatric conditions associated with drug 35 
abuse are urgently needed. Understanding the link between neurobiological mechanisms and 36 
behavior is a key aspect of elucidating drug abuse-related targets. Due to various molecular, 37 
biochemical, pharmacological, and physiological features, the zebrafish (Danio rerio) has been 38 
considered a suitable vertebrate for modeling complex processes involved in drug abuse 39 
responses. In this review, we discuss how the zebrafish has been successfully used for modeling 40 
neurobehavioral phenotypes related to drug abuse and review the effects of opioids, cannabinoids, 41 
alcohol, nicotine, and psychedelic drugs on the central nervous system (CNS). Moreover, we 42 
summarize recent advances in zebrafish-based studies and outline potential advantages and 43 
limitations of the existing zebrafish models to explore the neurochemical bases of drug abuse and 44 
addiction. Finally, we discuss how the use of zebrafish models may present fruitful approaches to 45 
provide valuable clinically translatable data. 46 
 47 
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1. Introduction 59 
Drug abuse is a public health problem with severe negative consequences for the 60 
individual and the society leading to increased risk for disability and premature death (WHO, 61 
2014). In 2015, 450,000 people died as a result of drug use (WDR, 2017), mortality that is mostly 62 
attributed to the use of legal drugs, such as tobacco and alcohol, and less so to illicit drugs 63 
(Peacock et al., 2018).  64 
The etiology of brain disorders caused by drug abuse is complex, involving a combination 65 
of factors that include individual genotype, social environment, and age or developmental stage 66 
(Samochowiec et al., 2014; Wall et al., 2016). In general, drugs act by changing neuronal function 67 
at molecular, cellular, circuitry, macro-structural, and numerous other functional levels leading to 68 
physiological and behavioral alterations (Berridge, 2017; Volkow et al., 2016). Understanding the 69 
link among genes, brain structure, neuronal function, and behavior is a key aspect of identifying 70 
new therapeutic targets aimed at pharmacological treatment of addiction (NIDA, 2016).  71 
Non-traditional model organisms, including the zebrafish (Danio rerio), have been 72 
successfully used for modeling complex processes involved in drug abuse responses (Mathur and 73 
Guo, 2010; Stewart et al., 2011). Neurobehavioral assays specifically developed or adopted for the 74 
zebrafish provide useful methods to explore reinforcing effects of drugs, and to study drug use 75 
associated phenomena including sensitization, tolerance, withdrawal, drug seeking, extinction, and 76 
relapse (Braida et al., 2007; Cachat et al., 2010; Darland and Dowling, 2001; Kily et al., 2008; 77 
Ninkovic and Bally-Cuif, 2006; Petzold et al., 2009). The zebrafish may serve as a valuable tool 78 
for high-throughput large scale behavioral screening for compounds (small molecules) affecting 79 
drug use and abuse-related responses as well as for mutations modifying drug effects. Such 80 
screens therefore may identify efficacious drugs as well as molecular targets for which such drugs 81 
may be developed in an efficient manner.   82 
Here, we discuss the growing utility of zebrafish models to investigate the neural 83 
mechanisms related to drug abuse, focusing on how opioids, cannabinoids, alcohol, nicotine, and 84 
psychedelic drugs influence neurochemical and behavioral functions in zebrafish. These drugs of 85 
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abuse were selected based on results from official world reports (WDR, 2017; WHO, 2014, 2015, 86 
2018) that demonstrate the high human consumption, prevalence and harmful health effects of 87 
these substances. 88 
 89 
2. Why zebrafish has been considered a suitable model organism for studying drug abuse? 90 
The zebrafish is a promising non-traditional organism for assessing the effects of drug 91 
abuse on the brain. Drug abuse-related research with both adult and larval zebrafish has been 92 
found to be translationally relevant. For example, due to the evolutionary conservation of 93 
biological mechanisms associated with drug abuse related processes between fish and mammals, 94 
the zebrafish have been found to respond to human (mammalian) drugs in a predictable manner 95 
(Klee et al., 2012; Stewart et al., 2011). Moreover, similar to humans, the zebrafish show drug 96 
abuse-related phenomena, including development of tolerance and withdrawal syndrome (Klee et 97 
al., 2012; Mathur and Guo, 2010; Meshalkina et al., 2017; Stewart et al., 2011). The advantages of 98 
zebrafish include low cost, prolific breeding, and ease of genetic manipulation (Parker et al., 2012; 99 
Rico et al., 2011; Stewart et al., 2014; Stewart et al., 2015a). Additionally, both larvae and adult 100 
zebrafish are easy to maintain and have small body size, other important characteristics that 101 
facilitate medium/high throughput screens (Bilotta et al., 1999; Kalueff et al., 2013). Furthermore, 102 
delivery of drugs or suspected efficacious compounds can be quite simple, as zebrafish may be 103 
immersed into drug solution from which the fish can rapidly absorb the drug through the gills and 104 
body surface (Rosemberg et al., 2012; Tran et al., 2015a). This method of drug delivery is 105 
effective for water soluble compounds but may also be employed with more lipophilic substances 106 
with the help of dimethyl sulfoxide (DMSO), a solvent to which zebrafish is relatively insensitive 107 
at lower concentrations (Altenhofen et al., 2017; Ibrahim et al., 2014). 108 
The zebrafish genome has been fully sequenced (Collier and Echevarria, 2013; Howe et 109 
al., 2013) and a number of genetic tools (e.g., efficient reverse and forward genetic methods) are 110 
available to investigate how various drugs modulate molecular functions in the vertebrate central 111 
nervous system (CNS) (Dooley and Zon, 2000; Rinkwitz et al., 2011). The zebrafish’s haploid 112 
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genome size is 1.7 gigabases, with 25 chromosomes, 12,062 known protein-coding genes and 113 
additional 7,465 predicted protein-coding genes (Klee et al., 2012). The nucleotide sequence of 114 
zebrafish genes shows approximately 70% homology with the human counterparts (MacRae and 115 
Peterson, 2015; Howe et al. 2013), and various orthologs involved with drug abuse-related 116 
processes have been described in the zebrafish (Table 1). Despite the apparent anatomical 117 
differences found between the teleost and the mammalian brain, the zebrafish brain has numerous 118 
areas that have been identified as homologous to mammalian brain regions serving similar 119 
functions to those of mammalian areas (Randlett et al., 2015; Ullmann et al., 2010). For example, 120 
the lateral pallium of the telencephalic area of the zebrafish is responsible for memory processing, 121 
a region homologous to the mammalian hippocampus, which is known to be the center of memory 122 
in mammals, similarly the zebrafish habenula is associated with fear responses, a brain area that 123 
corresponds to the mammalian amygdala (Agetsuma et al., 2010; Perathoner et al., 2016). 124 
Furthermore, dopaminergic projections of the zebrafish forebrain parallel the mesolimbic system 125 
involved in drug addiction in mammals (Rink and Wullimann, 2002). Although the genome 126 
duplication event in teleost fish modified the number of genes encoding proteins related to 127 
synthesis, transport and signaling within the neurotransmitter systems, the expression pattern of 128 
these proteins in zebrafish is similar to those of other vertebrates (Horzmann and Freeman, 2016). 129 
These features make the zebrafish a translationally relevant model organism, and considering that 130 
the zebrafish possesses relatively complex cognitive processing and decision-making abilities, one 131 
can argue that investigation of evolutionarily conserved phenotypes underlying drug abuse, 132 
reward and addiction should be possible using this species.  133 
Behavioral mechanisms underlying drug abuse can include sensitization, increased drug 134 
tolerance, withdrawal syndrome, drug seeking, extinction, and relapse. Behavioral phenomena 135 
related to the above together with underlying genetic mechanisms have been investigated using 136 
zebrafish (Klee et al., 2012; Stewart et al., 2011). Zebrafish neurobehavioral assays provide a 137 
suitable platform to explore drug response and their associated addiction related effects, such as 138 
withdrawal, locomotor activation, and drug seeking behavior (Cachat et al., 2010; Darland and 139 
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Dowling, 2001; Kily et al., 2008; Lau et al., 2006; Ninkovic and Bally-Cuif, 2006). The 140 
conditioned place preference (CPP) task is an often employed method to assess the rewarding 141 
properties of drugs, including morphine and ethanol, in zebrafish (Mathur et al., 2011b; Stewart et 142 
al., 2011; Webb et al., 2009). Behavioral responses following drug exposure in zebrafish have 143 
been found generally similar to those observed in humans or rodents (Meshalkina et al., 2017). 144 
Zebrafish larvae also display robust drug-evoked neurobehavioral phenotypes and offer one the 145 
ability to assess multiple animals simultaneously in a high-throughput manner (Stewart et al., 146 
2011). Moreover, genetic factors contribute to zebrafish behavioral responses, demonstrating a 147 
clear relationship among genes, reward phenotypes and withdrawal syndrome (Egan et al., 2009; 148 
Klee et al., 2012; Ninkovic and Bally-Cuif, 2006; Webb et al., 2009). Behaviors following 149 
withdrawal are frequently measured using the novel tank test (NTT), in which increased geotaxis 150 
(bottom dwelling), freezing, and erratic movements reflect anxiety-like responses that correlate 151 
with higher whole-body cortisol levels (Cachat et al., 2010). Importantly, adult zebrafish exibit a 152 
wide spectrum of behavioral phenotypes, which can be analyzed spatio-temporally using three-153 
dimensional automated video tracking tools (Cachat et al., 2011; Rosa et al., 2018; Rosemberg et 154 
al., 2011). Similarly to humans, withdrawal effects in zebrafish include sedation, altered 155 
sociability, and epileptic seizures (da Silva Chaves et al., 2018; Mathur and Guo, 2010; Muller et 156 
al., 2017). The above suggests that discovery of novel therapeutic approaches for treating drug 157 
abuse related disorders may be facilitated by research using zebrafish. Fig. 1 summarizes the most 158 
frequently utilized behavioral tests employed to assess the effects of drugs of abuse in zebrafish, 159 
and Table 2 lists the quantified phenotypes or endpoints measured in these tests.  160 
 161 
3. Limitations of zebrafish models to asesss the neurobehavioral mechanisms of drug abuse 162 
 The first limitation we want to emphasize is a fundamental question related to using 163 
animal models, and it may also be viewed as an advantage of the zebrafish. Fish are evolutionarily 164 
more primitive than mammals and thus one may not expect a fish model of, say drug addicition, to 165 
recapitulate all aspects of the mammalian, and the human, condition.  For this reason, a fish model 166 
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may only be employed as a simplified, “first-pass” approach, one with which the investigator may 167 
gain information about biological processes in a cost-effective manner.  However, the discoveries 168 
obtained using fish models must be subsequently verified using mammalian model organisms.  In 169 
other words, the zebrafish offers a reductionist approach that may speed up the discovery process.   170 
 Other limitations are more practical in nature. Although various experimental protocols 171 
have been successfully employed for modeling drug abuse and addiction in zebrafish (Table 3), 172 
such models present limitations. For example, usual indices of addiction, such as escalating self-173 
administration, CPP, relapse or reinstatement after extinction, and incubation, have either not been 174 
demonstrated in zebrafish, or have been published on only sporadically with some controversial 175 
data presented. For example, in zebrafish, some studies show anxiety-like behaviors after ethanol 176 
withdrawal (da Silva Chaves et al., 2018; Muller et al., 2017; Tran et al., 2015a), while other 177 
reports (Cachat et al., 2010) do not observe significant behavioral responses. Zebrafish have been 178 
found not to show reinforcement responses to all categories of drugs (e.g., cannabinoids), because 179 
some drugs or xenobiotics can trigger aversive responses rather than exhibiting rewarding 180 
properties required in CPP tests (Brock et al., 2017; da Rosa et al., 2016). Another limitation is 181 
that drug delivery via immersion of the fish in the drug solution is not feasible with lipohilic 182 
drugs, and this method of drug delivery is also complicated from the perspective of precise control 183 
of the amount of drug to be delivered. In addition, the pH of the drug solution also can influence 184 
the toxicity of the drug as well as its bioavailabity (Rubinstein, 2006). Perhaps the biggest 185 
disadvantage of the zebrafish in psychopharmacology is that knowledge of pharmacokinetics is 186 
still limited for this species, and the drug concentration that reaches different tissues is poorly 187 
explored (Chatterjee and Gerlai, 2009; Rosemberg et al., 2012). A seemingly trivial, but often 188 
encountered problem is that sexing zebrafish is not easy at the young age of these animals. 189 
Furthermore, due to the small size of this species certain procedures (e.g., injections) can 190 
constitute a methodological challenge. Another important limitation arises from the known 191 
genome duplication in teleosts (Glasauer and Neuhauss, 2014). Thus, investigation of certain 192 
molecular or genetic mechanisms may be complicated by multiplicity of functionally similar 193 
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molecular components not found in mammals. Although, some regards this as an advantage as 194 
knocking out particular gene targets may not lead to embryonic lethality and may only have a 195 
graded effect, allowing the analysis of the effects of reduced gene product. Furthermore, although 196 
the existence of distinct zebrafish strains (e.g., AB, TU, WIK, TL, WT, leopard) can serve as an 197 
interesting tool to assess how genes modulate drug response (Kenney et al., 2017; Quadros et al., 198 
2016; Rosa et al., 2018), differences in the genetic background and other experimental variables 199 
(e.g., housing, feeding, environmental factors) may influence behavioral data among laboratories 200 
(Gerlai, 2019; Parker et al., 2012). It is also notable that most “standard” strains of the zebrafish, 201 
including the above listed ones, are not fully inbred, and thus, unlike with mice, genetic stability is 202 
not warranted from generation to generation, and across laboratories (Gerlai et al., 2019). 203 
 Despite these limitations, however, the zebrafish has been found to be a valuable tool 204 
complementing the existing rodent literature in the analysis of numerous CNS disorders including 205 
those associated with drug abuse. This has been possible because most neurobiological 206 
phenomena share fundamental, evolutionarily ancient, conserved mechanisms that may be found 207 
both in fish and mammals. 208 
 209 
4. Ethanol 210 
4.1 General information 211 
  Socio-cultural traditions and behavioral stereotypes facilitate alcohol (ethanol, ethyl 212 
alcohol) consumption, and early experience with its use, easy access, relatively low cost and 213 
association with leisure activities may all contribute to the development of  alcohol use disorders 214 
(AUD) (Sudhinaraset et al., 2016). Social drinking elicits positive mood states and anxiety/stress-215 
relieving effects (Harrison et al., 2017; Hendler et al., 2013). However, long-term consumption 216 
may lead to AUD, which are classified as neuropsychiatric conditions, and the patients exhibit 217 
alcohol craving and alcohol seeking behavior (Reus et al., 2018). Alcohol abuse and alcoholism 218 
represent major public health issues due to their high prevalence and multidimensional health 219 
consequences, including complex brain alterations (Preuss et al., 2018; WHO, 2014). Alcohol is 220 
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the most harmful drug of abuse both in terms of its effects on the individual and on the society 221 
(Nutt et al., 2010; van Amsterdam et al., 2015; WHO, 2014). Indeed, alcohol consumption is 222 
responsible for approximately 5.9% of deaths worldwide and 5.1% of the global burden of 223 
diseases (WHO, 2014).  224 
 Compulsive alcohol consumers exhibit loss of behavioral control, as well as tolerance and 225 
withdrawal symptoms, which may include anxiety, depressive episodes, reduced sociability, 226 
insomnia, nausea, and epileptic seizures (Becker and Mulholland, 2014; Enoch et al., 2003). 227 
Importantly, both genetic and environmental factors influence the predisposition to alcoholism 228 
(Wall et al., 2016). Despite the remarkable impacts of AUD on public health, pharmacological 229 
treatments for alcohol dependence are substantially underutilized. The reason for lack of 230 
efficaceous drugs one could employ as pharmacotherapy for AUD is the lack of understanding of 231 
the effects of this pharmacologically and functionally complex drug (Antonelli et al., 2018; Goh 232 
and Morgan, 2017). 233 
 234 
4.2. Putative mechanisms of ethanol in the CNS 235 
   The effects of ethanol on brain functions occur from the low range to 100 millimolar, but 236 
the exact mechanisms involved in ethanol-mediated responses are not fully elucidated. Different 237 
from other psychotropic drugs, ethanol has a rather complex pharmacological effect profile in the 238 
CNS, influencing several molecular targets and biochemical reactions directly and an even larger 239 
number of these mechanisms indirectly. Ethanol easily crosses the blood–brain barrier and 240 
modulates brain activity, thereby affecting behavior in a dose-dependent manner (Esel and Dinc, 241 
2017; Spanagel, 2009). Acute exposure to low to moderate doses of ethanol promote disinhibition 242 
of punished behavior, euphoria, and anxiolysis, while higher doses induce sedation, lack of 243 
coordination, somnolence, and memory impairments (Hendler et al., 2013). Chronically, ethanol 244 
induces neuroadaptive processes and triggers tolerance, dependence, and withdrawal syndrome, 245 
which include psychiatric symptoms, overt neurotoxicity, and severe cognitive disruptions 246 
(Abrahao et al., 2017; Banerjee, 2014; Hammoud and Jimenez-Shahed, 2019).  247 
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  Ethanol modulates both excitatory and inhibitory signal transduction pathways in the 248 
CNS (Chastain, 2006; Esel and Dinc, 2017). Ethanol decreases metabolic activity (Wang et al., 249 
2000), inhibits glutamatergic neurotransmition (Hwa et al., 2017; Roberto and Varodayan, 2017), 250 
and potentiates gamma-aminobutyric acid- (GABA) and glycine-mediated synapses (Breese et al., 251 
2006; Soderpalm et al., 2017; Zhu and Lovinger, 2006). Additionally, ethanol reduces the 252 
transmembrane flow of calcium (Ca2+) by inhibiting the functioning of L-type Ca2+ channels 253 
(Hendricson et al., 2003), which play a key role in ethanol-induced depressive behaviors (Dopico 254 
et al., 2014), CPP (Hill et al., 2003; Newton et al., 2008), and neuroadaptation (Mulholland et al., 255 
2011; Nimitvilai et al., 2016). Impaired CNS homeostasis is associated with ethanol-induced 256 
sedative and anxiolytic effects (Lovinger and Roberto, 2013), as well as memory deficits affecting 257 
cognitive performance (Costardi et al., 2015; Lovinger and Roberto, 2013; Weiss et al., 2014). 258 
  Ethanol indirectly activates dopaminergic and serotonergic neurons, which innervate the 259 
reward system (Erdozain and Callado, 2014). Low ethanol doses increase dopamine and serotonin 260 
release, thereby facilitating reinforcement (Morel et al., 2018; Nutt et al., 2015), and emotion-261 
related behaviors (Marcinkiewcz, 2015), respectively. Conversely, chronic ethanol consumption 262 
reduces both dopamine and serotonin levels, and negative emotional states are observed during 263 
ethanol withdrawal. Ethanol also affects the homeostasis of cholinergic (Davis and de Fiebre, 264 
2006; Hendrickson et al., 2013), noradrenergic (Haass-Koffler et al., 2018; Rossetti et al., 1992), 265 
opioid (Costardi et al., 2015; Gianoulakis, 2009), and endocannabinoid (Lavanco et al., 2018; 266 
Sloan et al., 2017) systems (see details in Fig. 2A). These sets of mechanisms help explain how 267 
ethanol modulates learning, memory, as well as the rewarding properties of ethanol (White, 2003; 268 
Zorumski et al., 2014). 269 
  A number of proteins with ethanol-binding sites have been identified. These include 270 
enzymes involved in ethanol pharmacokinetics, such as alcohol and acetaldehyde dehydrogenases 271 
(ADH/ALDH), cytochrome P450 2E1 (CYP2E1), and adenylyl cyclase – an enzyme that produces 272 
the second messenger adenosine 3′,5′-monophosphate (cAMP) from adenosine triphosphate 273 
(ATP) (Pereira et al., 2015; Yoshimura et al., 2006). Corticotropin releasing factor (CRF) plays an 274 
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important role on stress-induced relapses to ethanol drinking because its positive regulation is 275 
directly involved in negative emotional states (Heilig and Koob, 2007). Acute and chronic ethanol 276 
consumption also modulates cAMP-responsive element binding (CREB) protein in the brain 277 
(Morrow et al., 2004), and downstream effects on several important CREB-related genes, such as 278 
neuropeptide Y (NPY), brain derived neurotrophic factor (BDNF), activity-regulated cytoskeleton-279 
associated protein (ARC), and corticotrophin-releasing hormone (CRH). These CREB-related 280 
genes play a crucial roles in the genetic predisposition to alcoholism contributing to the behavioral 281 
effects of ethanol (Moonat et al., 2010). 282 
 283 
4.3. Ethanol and zebrafish: neurobehavioral studies 284 
    The first study to analyze the behavioral effects of acute ethanol exposure in zebrafish 285 
date from 2000, a study in which ethanol was found to elicit a range of behavioral changes 286 
analogous to what was found in mammals (Gerlai et al., 2000). For example, low-to-moderate 287 
concentrations (0.25 and 0.5% v/v) of ethanol increased locomotor activity while higher 288 
concentrations (1.0% v/v) inhibited locomotion, causing sedation in the zebrafish (Gerlai et al., 289 
2000). Importantly, ethanol-mediated effects on behavior have been found concentration- and 290 
time-dependent, effects that correlated with changes in brain ethanol levels (Rosemberg et al., 291 
2012). After acute exposure to low-to-moderate ethanol concentrations, a substantial decrease in 292 
anxiety-like behaviors, such as erratic movement (Egan et al., 2009), freezing (Blaser and 293 
Penalosa, 2011), predator induced avoidance (Pannia et al., 2014), and bottom dwelling (Wong et 294 
al., 2010) have been reported in zebrafish. At lower concentrations, ethanol also triggers 295 
aggressive behavior, affects shoaling, and modulates fear-like responses (Fontana et al., 2016; 296 
Fontana et al., 2018b; Gerlai, 2003; Gerlai et al., 2000). Brief ethanol exposure (1.5% v/v for 20 297 
min) have also been found to enhance ethanol preference in a CPP paradigm, confirming 298 
positively-reinforcing properties of ethanol in zebrafish (Mathur et al., 2011a; Mathur et al., 299 
2011b).  300 
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   Acute ethanol exposure increases dopaminergic and serotonergic activity in the brain of 301 
AB zebrafish (Chatterjee and Gerlai, 2009; Chatterjee et al., 2014; Tran et al., 2016; Tran et al., 302 
2015c). However, ethanol decreases the levels of aspartate, taurine, GABA, glutamate and glycine 303 
in a concentration-dependent manner (Chatterjee et al., 2014). Furthermore, ethanol acutely 304 
enhances acetylcholinesterase activity and alters antioxidant defenses by decreasing superoxide 305 
dismutase (SOD) and increasing catalase (CAT) activities, which result in lipid peroxidation 306 
(Rosemberg et al., 2010). Ethanol acutely stimulates mitochondrial respiration and consequently 307 
the bioenergetics eficience, reinforcing the ethanol stimulatory effect on mitochondrial O2 308 
consumption (Müller et al., 2019). Mounting data also support the involvement of purinergic 309 
signaling in ethanol-mediated responses, since ethanol and its metabolite, acetaldehyde, modulate 310 
the hydrolysis of extracellular nuceleotides in zebrafish (Rico et al., 2007; Rico et al., 2008). 311 
Because zebrafish neurotransmitter systems show a robust functional correspondence and 312 
homology compared to those of mammals, investigators have concluded that the main functions, 313 
enzymes, receptors, transporters affected by ethanol are evolutionarily conserved (Cox et al., 314 
2005; Kaslin et al., 2004; Kim et al., 2004; Maximino et al., 2013; Moly et al., 2014; Panula et al., 315 
2006; Rico et al., 2003; Senger et al., 2004). 316 
   Protocols for studying ethanol tolerance and withdrawal (Dlugos and Rabin, 2003; Gerlai 317 
et al., 2009; Mathur and Guo, 2011; Tran et al., 2015b) have been validated for zebrafish. 318 
Administration can be performed by using an intermittent (Mathur and Guo, 2011; Muller et al., 319 
2017) or a continuous (Damodaran et al., 2006; Dlugos and Rabin, 2003; Egan et al., 2009) 320 
ethanol exposure. Both protocols induce tolerance to the locomotor stimulant, anxiolytic, and 321 
anxiogenic effects of ethanol. The inttermitent protocol provides translational relevance because it 322 
mimics the ethanol consumption observed in humans. This repeated ethanol exposure elicits 323 
defensive responses by stimulating social behavior, geotaxis, and scototaxis, which reflect 324 
anxiogenesis (Muller et al., 2017). These behavioral responses can be associated with changes in 325 
oxidant processes in the brain since ethanol decreases antioxidant defenses like SOD and CAT 326 
activities and non-protein thiol (NPSH) levels, and increases lipid peroxidation (Muller et al., 327 
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2017). Intermittent ethanol exposure also impairs the eletrons flow between I- and II- complexes 328 
of mitochondrial electron transport chain, which is associated with ROS formation (Müller et al., 329 
2019). 330 
   Continuous ethanol exposure appears to lead to a more robust level of tolerance and 331 
removes the potential effects of repeated withdrawal from the drug as it happens in the repeated 332 
intermittent protocol. After continuous ethanol exposure, AB zebrafish show increased levels of 333 
dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), serotonin, 5-hydroxyindoleacetic acid 334 
(5HIAA), glutamate, aspartate, and glycine in the CNS following withdrawal (Chatterjee et al., 335 
2014). Zebrafish continually exposed to ethanol also exhibit decreased choline acetyltransferase 336 
activity, changes in antioxidant enzymatic defenses, and increased reactive oxygen species 337 
production (Agostini et al., 2018). Continuous chronic exposure followed by ethanol withdrawal 338 
also impairs aversive learning in the inhibitory avoidance learning task (Amorim et al., 2017; 339 
Luchiari et al., 2015). Withdrawal protocols using zebrafish have also produced some conflicting 340 
results. Some studies report robust effects of withdrawal on anxiety-like behavior (da Silva 341 
Chaves et al., 2018; Muller et al., 2017; Tran et al., 2015a), while other reports (Cachat et al., 342 
2010) do not observe significant behavioral responses. A possible explanation for data 343 
heterogeneity may be related to differences in ethanol concentration (e.g., 0.25, 0.5, or 1.0 % (v/v) 344 
concentration range) and exposure period (e.g., acute vs. chronic, intermittent or continuous 345 
exposure) employed in a wide range of protocols (Cachat et al., 2010; da Silva Chaves et al., 346 
2018; Chatterjee et al., 2014; Müller et al., 2017). 347 
    A model of voluntary ethanol intake, using ethanol mixed with gelatin, has been 348 
characterized in zebrafish. Stimulatory effects on locomotion, reduced anxiety, potentiation of 349 
aggressive behaviors, and increased expression of galanin (gal) and orexin (ox) in specific 350 
hypothalamic areas were observed (Sterling et al., 2015). Importantly, the effects of ethanol on 351 
brain circuitry and behavior of zebrafish may occur in a strain-dependent manner (de Esch et al., 352 
2012; Dlugos and Rabin, 2003; Gerlai et al., 2009), as well as dependent on the time of the day in 353 
which ethanol is administered (Tsang et al., 2018; Vera et al., 2018).  354 
14 
 
 In addition to the analysis of the effects of acute and chronic ethanol administration, 355 
investigation of the consequences of embryonic ethanol exposure has also been started using the 356 
zebrafish. The goal of this research has been to model behavioral and physiological phenotypes 357 
associated with human fetal alcohol spectrum disorders (FASD). Some features as high fecundity, 358 
external fertilization, embryo transparency and rapid development, make the zebrafish especially 359 
well-suited for modeling and studying the pathology of FASD (Lovely et al., 2016). Early 360 
zebrafish FASD models recapitulated some features of gross morphological abnormalities seen in 361 
the most severe forms of fetal alcohol syndrome (Carvan et al., 2004). More recently, however, 362 
attempts have been made to model the milder and more prevalent forms of FASD. These studies 363 
found lasting behavioral defects without apparent morphological abnormalities, particularly in the 364 
domains of social behavior (shoaling) and anxiety-like responses (Fernandes et al., 2019; Parker et 365 
al., 2014), cognition, learning and memory (Amorim et al., 2017; Cleal and Parker, 2018; Lutte et 366 
al., 2018), with higher concentrations of ethanol also leading to structural defects in various 367 
tissues (brain, sensory organs, heart and craniofacial phenotypes) (Baggio et al., 2018; Fernandes 368 
et al., 2018; Ramlan et al., 2017). Embryonic ethanol exposure, changes the expression of genes 369 
involved in developmental processes, such as development of the neural tube, forebrain, and eye 370 
formation (six3b and glil), resulting in altered somite development, decreased body length, and 371 
intraocular distance (Loucks and Ahlgren, 2012). Moreover, early embryonic ethanol exposure 372 
has been found to impair neurotransmitter systems, including the serotoninergic, dopaminergic 373 
(Baggio et al., 2018; Buske and Gerlai, 2011; Mahabir et al., 2018) and purinergic systems in 374 
zebrafish (Lutte et al., 2018). In summary, both larval and adult zebrafish have been successfully 375 
used to explore the neurobehavioral mechanisms involved in ethanol abuse and addiction. 376 
 377 
5. Opioids  378 
5.1. General information 379 
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Opioids are a class of drugs that include opiates (e.g., opium, diamorphine, morphine, 380 
codeine, thebaine, and oripavine) and semi- and synthetic drugs (e.g., meperidine, pethidine, 381 
hydromorphone, methadone, hydrocodone, oxycodone, and fentanyl) that have similar actions to 382 
those of opiates (Volkow et al., 2011). Non-medical use of opioids is considered a major public 383 
health challenge in the last two decades (CBHSQ, 2015). The repeated exposure to escalating 384 
dosage of opioids can result in development of tolerance, addiction (intense drug craving and 385 
compulsive use), and dependence (to avoid a withdrawal syndrome) (Kosten and George, 2002).  386 
Opioid dependence and addiction are serious, chronic, and often relapsing disorders of the 387 
CNS associated with altered brain homeostasis (Kolodny et al., 2015). The brain abnormalities 388 
that produce addiction are complex and long-lasting, and are influenced by environmental (e.g., 389 
stress, social context, and psychological conditioning) as well as genetic factors (e.g brain 390 
pathways that were abnormal even before the first dose of opioid was taken) (Kosten and George, 391 
2002). Altered brain function can produce craving that leads to relapse months or even years after 392 
the last use of the drug (Koob and Volkow, 2010). Opioid dependence and addiction are 393 
considered chronic diseases, like hypertension, schizophrenia, and diabetes (Dennis and Scott, 394 
2007). Thus, novel therapeutical strategies for treating drug addiction are necessary, and novel 395 
approaches to circunvemt opioid addiction are imperative. 396 
 397 
5.2. Putative mechanisms of opioids in the CNS 398 
Opioid molecules travel in the bloodstream to the brain and attach to specific proteins at 399 
the surfaces of opiate-sensitive neurons, known as opioid receptors (Kosten and George, 2002). In 400 
humans, there are three classical opioid receptors: the mu-opioid receptor (MOP), the kappa-401 
opioid receptor (KOP), and the delta-opioid receptor (DOP), encoded by the genes OPRM1, 402 
OPRK1, and OPRD1, respectively (Al-Hasani and Bruchas, 2011). These genes encode G-403 
protein-coupled receptors that interact with heterotrimeric (Gi/Go) G proteins (Dhawan et al., 404 
1996). Opioids activate the mesolimbic (mindbrain) reward system, which plays a role in 405 
motivating the user to repeatedly abuse the drug (Ikemoto, 2010). This pathway is mainly 406 
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responsible for generating signals in the ventral tegmental area (VTA), culminating in the release 407 
of dopamine in the nucleus accumbens (NAc) that causes feeling of pleasure (Adinoff, 2004). 408 
Opioids also affect other brain areas involved in associative learning and memory, which associate 409 
good feelings with the environment in which they occurred (Volkow et al., 2002). These 410 
memories often result in drug craving when abusers reencounter this environment (e.g., person, 411 
places, or objects), facilitating drug use relapse and abuse (Kosten and George, 2002). In early 412 
stages, the opioid’s stimulation of reward systems is the primary reason for drug-seeking 413 
behavior. However, the compulsion to use opioids is constantly increased and after repeated 414 
exposure to the drug is also driven by developed tolerance leading to drug dependence in the 415 
patient (Koob and Le Moal, 2001).  416 
Mounting evidence suggests that tolerance and dependence-like phenomena can occur at 417 
cellular levels and include changes in cyclic adenosine 3′,5′-monophosphate (cAMP) dependent 418 
biochemical pathways (Anand et al., 2010; Dhawan et al., 1996; Gupta and Kulhara, 2007; 419 
McFadzean, 1988; Sharma et al., 1977). Furthermore, the chronic use of morphine results in a 420 
feedback inhibition of endogenous opioid synthesis as it decreases/increases the expression of 421 
proenkephalin mRNA and enkephalin peptides depending on the cell type affected (Gonzalez-422 
Nunez et al., 2013; Le Merrer et al., 2009). Although opioid-induced changes in the above 423 
mentioned genes are a key factor related to opioid addiction and withdrawal, the mechanisms 424 
underlying addiction involve a potentially large number of other factors, leading to alterations in 425 
the dopaminergic system (Volkow, 2010), ion conductance (Grudt and Williams, 1995), cAMP 426 
(Chan and Lutfy, 2016; Dziedzicka-Wasylewska and Przewlocki, 1995), endogenous ligands 427 
(Weber, 1983), and glutamate (Peters, 2012) all contributing drug-seeking behavior in a complex 428 
manner (see details in Fig. 2B). Clearly, further studies are necessary to elucidate the mechanistic 429 
complexity underlying chonic effects of opioids.  430 
 431 
5.3. Opioids and zebrafish: neurobehavioral studies 432 
17 
 
Zebrafish have an evolutionarily conserved opioid system, which makes this fish a 433 
valuable tool for studying the molecular bases of human opioid addiction. The initial studies 434 
related to opioid system in zebrafish analyzed ZFOR1, a delta-opioid receptor isolated using a 435 
probe from rat MOP (Barrallo et al., 1998). Phylogenetic analyses showed a high degree of 436 
nucleotide sequence conservation for all opioid receptor genes of zebrafish when compared to 437 
their respective human counterparts (Dreborg et al., 2008). Orthlogs of three classical human 438 
opioid receptors were characterized in zebrafish (Stevens, 2009). While the oprm1, oprk1, oprl1 439 
genes have single homologs in zebrafish, a pair of oprd1 can be found in this species (Herrero-440 
Turrion et al., 2014).  441 
As it occurs in rodents, opioid drug exposure results in behavioral changes, affecting 442 
locomotion and anxiety-like response in the zebrafish too. For example, diacetylmorphine (heroin) 443 
evokes hyperlocomotion without changing anxiety-like behaviors in zebrafish (Stewart and 444 
Kalueff, 2014). Although morphine elicits analgesia in zebrafish (Costa et al., 2019; Magalhaes et 445 
al., 2017; Taylor et al., 2017), exposure to this drug can also have anxiolytic effects in zebrafish 446 
and decrease erratic movements and increase the time spent near the water surface in the NTT 447 
(Wong et al., 2010). The larval zebrafish exhibits preference for morphine in the choice chamber 448 
test, and such response is attenuated by opioid and dopamine antagonists (Bretaud et al., 2007).  449 
Dopaminergic and serotonergic neurons have been shown to play essential roles in drug-450 
seeking behavior in humans (Rogers, 2011). Confirming such findings, adult zebrafish exhibit 451 
increased conditioned preference for both food and morphine, a response that is blocked by 452 
naloxone (an opioid antagonist) as well as by dopamine receptor antagonists (Lau et al., 2006). 453 
Other opioid drugs such as fentanyl, oxycodone, tetracaine, phencyclidine, and chlorpheniramine 454 
also exhibit rewarding proprieties in zebrafish CPP test (Brock et al., 2017). Importantly, a 455 
method of self-administration of opioids has been recently developed for the zebrafish (Bosse and 456 
Peterson, 2017), providing a novel tool for assessing drug addiction in this species. Briefly, 457 
zebrafish shoals trained for five days were found to self-administer hydrocodone hydrochloride, a 458 
MOP-dependent behavior blocked by dopamine and glutamate receptor antagonists (Bosse and 459 
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Peterson, 2017). Finally, drug withdrawal induced responses have also been observed in zebrafish: 460 
increased anxiety-like behaviors and whole-body cortisol levels have been found (Cachat et al., 461 
2010). The above results demonstrating robust drug seeking-behavior and withdrawal responses 462 
reinforce the utility of zebrafish as a vertebrate model organism appropriate for studying the 463 
molecular bases underlying opioid addiction and dependence processes. 464 
 465 
6. Nicotine 466 
6.1 General informations 467 
 Nicotine is an alkaloid found in tobacco plants that affects the CNS in a varied manner 468 
(Jaffe and Kanzler, 1979; Levin and Chen, 2004; Levin and Rezvani, 2000). This alkaloid the 469 
major active constituent of tobacco responsible for the development of smoking induced drug 470 
dependence (Stolerman and Jarvis, 1995). Nicotine addiction is considered a chronic brain 471 
disorder, and tobacco smoking represents a risk factor for developing several chronic diseases, 472 
including cancers and cardiovascular disorders (Berrendero et al., 2010). Smoking-related 473 
diseases are serious world health problems since tobacco use alone causes approximately six 474 
million deaths per year worldwide (WHO, 2015). According to recent estimates, there are nearly 475 
1.3 billion of smokers in the world, making tobacco smoking one the most prevalent addiction 476 
over the world (D'Souza, 2016). Various factors contribute to nicotine addiction, including 477 
chronic stress, low socioeconomic status, individual susceptibility, etc. (Jarvis, 2004; Morris et al., 478 
2016). Moreover, psychiatric disorders, including schizophrenia, bipolar disorder and depression 479 
also increase susceptibility to smoking (Lucatch et al., 2018; Suemaru et al., 2006). Smoking 480 
induces changes in the brain that can lead to nicotine craving, relapse, and withdrawal induced 481 
symptoms (Bruijnzeel, 2017). Despite pharmacological treatments available to combat nicotine 482 
addiction, the number of smokers remains high and smoking related health issues continue to 483 
represent a major medical problem (Herman et al., 2014). 484 
 485 
6.2 Putative mechanisms of nicotine in the CNS 486 
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  After smoking, nicotine is absorbed into the blood through the lungs and reaches the 487 
brain in ten seconds (Benowitz, 2009). Nicotine absorption is pH-dependent, where nicotine is 488 
non-ionized and quickly crosses cellular membranes at physiological pH (Le Houezec, 2003). 489 
Nicotine interacts with a number of nicotinic acetylcholine receptors (nAChRs) that are formed as 490 
homopentamers and heteropentamers from subunits in the CNS (Gotti et al., 2009). In the 491 
mammalian brain, there are eight α subunits (α2–α10) and three β subunits (β2–β4) (Karlin, 2002; 492 
Subramaniyan and Dani, 2015), and the most commonly expresses are α4β2 or α7 nAChR (Dani 493 
and Bertrand, 2007).  494 
 Nicotine activates nAChRs and promotes the release of various neurotransmitters 495 
including acetylcholine, dopamine, serotonin, GABA, glutamate, and norepinephrine in the brain 496 
(Alkondon et al., 2000; Dani and Bertrand, 2007; Dehkordi et al., 2018; Gao et al., 2010; 497 
Mansvelder et al., 2002; Mao et al., 2011; Wonnacott, 1997). Nanomolar concentrations of 498 
nicotine enhance both glutamatergic and cholinergic neurotransmission (McGehee et al., 1995). 499 
Nicotine also stimulates the release of GABA in the rodent brain (Zhu and Chiappinelli, 1999), 500 
and increases the firing rate of dopaminergic and non-dopaminergic neurons (Yin and French, 501 
2000). The activation of nAChRs increases intracellular levels of Ca2+ (De Biasi and Dani, 2011; 502 
Nakayama and Nakashima, 2004), and modulates both the opioid and endocannabinoid systems 503 
(Maldonado and Berrendero, 2010; Maldonado et al., 2006; Zarrindast and Khakpai, 2018). 504 
Importantly, the broad action of nicotine via nAChRs in the brain modulates anxiety, learning, 505 
memory, pain, body weight and temperature (Zarrindast and Khakpai, 2018).  506 
 Nicotine dependence has different phases (D'Souza and Markou, 2013). The acquisition 507 
and maintenance of nicotine seeking occurs by the positive reinforcing effects of nicotine (e.g., 508 
mild euphoria, relaxation, increased arousal, and decreased fatigue) (Henningfield et al., 1985). 509 
Chronically, nicotine induces neuroadaptation in the brain reward systems, leading to the 510 
development of dependence (D'Souza and Markou, 2013). The rewarding properties of nicotine 511 
are mediated by dopaminergic neurons in the mesocorticolimbic system (Zarrindast and Khakpai, 512 
2018). Stimulation of the α4β2 nAChR of the dopamine cell bodies in the VTA results in 513 
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dopamine release in the NAc and prefrontal cortex (PFC) (Herman et al., 2014). Similarly to the 514 
effects of some other drugs of abuse, nicotine induced increase of dopamine in the NAc mediates 515 
the rewarding and pleasurable effects of this drug, which is considered the mechanism responsible 516 
for initiation and maintenance of nicotine addiction (Herman et al., 2014). When nicotine 517 
administration is stopped, withdrawal symptoms appear (D'Souza and Markou, 2013). In humans, 518 
withdrawal produces negative affective effects, such as depressed mood, dysphoria, irritability, 519 
anxiety, and craving (Shiffman and Jarvik, 1976). The “physical” or somatic symptoms include 520 
insomnia, gastrointestinal discomfort, bradycardia, and increased appetite (Hughes et al., 1991). 521 
Besides of nAChR, opioid and endocannabinoid systems, neuropeptides, and changes in signal 522 
transduction pathways are also implicated in nicotine withdrawal syndrome (Jackson et al., 2015). 523 
After the development of nicotine dependence, the endogenous release of CRF and the resulting 524 
negative mood state can drive nicotine intake (negative reinforcement) (Bruijnzeel, 2017). These 525 
pathways have been considered key targets for the development of new treatments to reduce 526 
withdrawal symptoms (Bruijnzeel, 2017; D'Souza, 2016; Jackson et al., 2015).  527 
 Nicotine target proteins and enzymes related to nicotine pharmacokinetics include the 528 
liver enzymes cytochrome P450 2A6 (CYP2A6), UDP glucuronosyltransfease (UGT), flavin-529 
containing monooxygenase (FMO) (Benowitz, 2009). Nicotine also promotes neuroadaptation by 530 
increasing cAMP-responsive element-binding protein (pCREB) levels in dopaminergic neurons 531 
after chronic administration of this drug. Nicotine exposure in adolescent rats also suppresses 532 
basal adenylyl cyclase activity and eventually compromises the response to beta-adrenergic 533 
receptor stimulation, culminating in several alterations of neural circuits in adulthood (Slotkin et 534 
al., 2008). Although BDNF levels do not change during chronic exposure to nicotine, a prominent 535 
increase of the level of this neurotorphic factor is observed in the NAc, VTA, and substantia nigra 536 
during abstinence from nicotine (Kivinummi et al., 2011). Overall, experimental findings support 537 
the involvement of BDNF and pCREB in nicotine-induced neurochemical changes observed in 538 
dopaminergic neurons. Specific mechanisms involved in the effects of nicotine on the CNS are 539 




6.3  Nicotine and zebrafish: neurobehavioral studies 542 
The zebrafish has been argued to be a suitable tool to study the effects of nicotine on the 543 
CNS (Braida et al., 2014).  Eight zebrafish neuronal cDNA of nAChRs subunits have been cloned 544 
(α2, α3, α4, α6, α7, β2, β3, and β4) (Ackerman et al., 2009; Papke et al., 2012; Welsh et al., 2009; 545 
Zirger et al., 2003), showing high degree of similarities (nucleotide sequence homologies across 546 
genes) when compared to their respective human and rat orthologs (Papke et al., 2012). 547 
Importantly, the well-known nAChR antagonists (e.g., mecamylamine and dihydro-β-548 
erythroidine) reverse the effects of nicotine in zebrafish just like in mamals, supporting the notion 549 
that there is strong conservation between zebrafish and humans nAChR (Bencan and Levin, 2008; 550 
Eddins et al., 2009; Levin et al., 2006). 551 
During the last decade, several studies aiming to understand how nicotine influences 552 
zebrafish behavior and memory have been performed (Cousin et al., 2014; Faillace et al., 2017; 553 
Klee et al., 2012). Acute nicotine exposure alters the shoal polarization (coordinated directional 554 
movement of shoal members) and reduces social cohesion (increases inter-individual distance) in 555 
zebrafish (Miller et al., 2013). Moreover, nicotine attenuates contextual fear-like responses in 556 
zebrafish exposed to conspecific alarm substance, and a putative role of cholinergic signaling in 557 
aversive memory has also been predicted in this species (Ziani et al., 2018).  Nicotine also exerts a 558 
dual role in anxiety-like behavior in zebrafish similarly to mammals (Levin et al., 2007; 559 
Sackerman et al., 2010; Singer et al., 2016), whereby acute exposure has anxiolytic (Sackerman et 560 
al., 2010), and chronic exposure anxiogenic effects (File et al., 2000; Stewart et al., 2015b). 561 
Nicotine administered acutely may reduce swimming speed, increase vertical activity in an open 562 
tank task in both male and female zebrafish (Singer et al., 2016). Furthermore, both α7 and α4β2 563 
nicotinic receptors play a role in nicotine-mediated reduction of anxiety-like responses in 564 
zebrafish (Bencan and Levin, 2008).  565 
 When administered chronically, nicotine induces conditioned place preference (CPP) in 566 
zebrafish (Faillace et al., 2017), and this effect may persist even after 3 weeks of abstinence from 567 
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the drug (Kily et al., 2008). Moreover, changes in the expression of 868 genes from adult 568 
zebrafish brain (50:50 male:female ratio) were detected following 30 µmol/L nicotine exposure 20 569 
min each day over a 4-week period (Kily et al., 2008). Conversely, CPP-mediated reinforcing 570 
effects were blocked when nicotine was co-administered with cystine derivates, showing that this 571 
response was due to binding to high-affinity heteromeric receptors (except α7 receptors) and that 572 
these molecules may contribute to the induction of smoke cessation (Ponzoni et al., 2014).   573 
 Evidence shows that nicotine, similarly to its effects in mammals, improves cognitive 574 
function in zebrafish (Levin and Chen, 2004; Levin et al., 2006; May et al., 2016). For example, 575 
nicotine increases the discrimination index in a virtual object recognition test (VORT) (Braida et 576 
al., 2014), enhances familiar object preference (May et al., 2016), and at lower doses improves 577 
memory in a delayed spatial alternation test (Levin and Chen, 2004). In zebrafish, the VORT 578 
evaluates the selective attention behavior using 2D geometrical shapes, located on two opposite 579 
walls of the tank. Each fish is subjected to a familiarization trial, and the discrimination index is 580 
calculated at different time intervals (5 min to 96 h) following the novel shape recognition (Braida 581 
et al., 2014). Nicotine significantly improves the percent of correct accuracy in the spatial position 582 
discrimination test (Levin et al., 2006). This latter positive effect was observed 20–40 min post 583 
administration, and declined after 80 and 160 min (Levin et al., 2006). Interestingly, the neural 584 
bases associated with the positive effects of nicotine on learning in zebrafish involve the 585 
dopaminergic system, because nicotine exposure increases both acquisition rates and DOPAC 586 
(metabolite of dopamine) levels in the brain (Eddins et al., 2009). Furthremore, nAChRs play a 587 
modulatory role in zebrafish cognition, and learning performance changes in an inverted U-shaped 588 
nicotine dose-dependent manner with moderate nicotine doses improving while high doses 589 
impairing learning performance (Braida et al., 2014). 590 
 Nicotine exposure in Danio rerio gill (DrG) cell lines and gill tissue causes depletion of 591 
antioxidant enzymes, leading to reduced glutathione (GSH), SOD, CAT, glutathione S-transferase 592 
(GST) and glutathione peroxidase (GPx1a) (Nambi, 2017). Nicotine also increases lipid 593 
peroxidation and the expression of apoptosis-related genes, p53 and cas3 (Nambi, 2017). 594 
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Importantly, nicotine has embryotoxic effects and its administration during embryonic 595 
development leads to abnormal morphology and impaired heart rate (Yoo et al., 2018). Acute 596 
exposure increases embryonic motor output (Thomas et al., 2009), and evokes locomotor 597 
responses in zebrafish embryos 36 hours post-fertilization (hpf) (Mora-Zamorano et al., 2016), 598 
whereas chronic larval exposure results in changes in notochord length, reduced eye diameter, 599 
altered behavior and decreased survival (Parker and Connaughton, 2007). Moreover, adult female 600 
zebrafish exposed to nicotine exhibit downregulation of expression of myelin-related transcription 601 
regulators. Because myelin plays a key role in the nervous system, deficits in myelin are often 602 
related to various neuropsychiatric conditions and drug addiction (Zhao et al., 2014). 603 
 604 
7. Cannabinoids  605 
7.1  General information 606 
  For many centuries, Cannabis sativa has been used due to its psychoactive and medicinal 607 
properties (Ameri, 1999). About 147 million people consume cannabis worldwide (WHO, 2018) 608 
and approximately 13.1 million people are cannabis-dependent (Degenhardt et al., 2013). The 609 
extract of cannabis contains over 100 compounds called cannabinoids (CB), classified as a 610 
collective group of molecules that act on cannabinoid receptors. The most abundant CB is Δ9-611 
tetrahydrocannabinol (Δ9-THC), its precursor cannabidiol (CBD), and cannabinol (CBN) (Panlilio et 612 
al., 2015). CBD and CBN do not exhibit the psychoactive properties of Δ9-THC, but have clinical 613 
interest because their antipsychotic, anticonvulsive, neuroprotective, and anxiolytic effects (Bonini 614 
et al., 2018; Izzo et al., 2009; Niesink and van Laar, 2013).  615 
  Interaction between genetic and environmental factors explain psychological, social, and 616 
physiological effects of cannabis following acute as well as long-term consumption (Danielsson et 617 
al., 2016). Inhalation of C. sativa smoke is the generally preferred route of administration because it 618 
produces rapid effects. Acute effects last for approximately 2–3 h and are often described as 619 
pleasant and relaxing (Panlilio et al., 2015). Δ9-THC mainly acts on the CNS, producing a mixture 620 
of psychotomimetic and depressant effects, along with several centrally mediated autonomic effects 621 
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(Curran et al., 2016). The mixture of depressant and stimulant effects is characterized by euphoria, 622 
talkativeness, sedation, easy laughter, distortion of time perception, increased perception of external 623 
stimuli, and memory lapses (Fratta and Fattore, 2013). Users typically experience peripheral effects, 624 
such as increased appetite, dry mouth, tachycardia, increased blood pressure, and bronchodilation 625 
(Panlilio et al., 2015). Overall, chronic CB use is associated with addiction, which results in 626 
cognitive impairment, poor educational outcome, diminished life satisfaction and achievement, and 627 
increased risk of psychotic disorders (Fratta and Fattore, 2013; Volkow et al., 2014). 628 
 629 
7.2  Putative mechanisms of cannabinoids in the CNS 630 
  The first studies investigating the biology of cannabinoid signaling were conducted shortly 631 
after the two primary receptors, cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2), 632 
were cloned in the early 1990s (Matsuda et al., 1990; Munro et al., 1993). CB1 and CB2 are 633 
transmembrane G-protein coupled receptors (GPCR) well-conserved in vertebrates. CB1 is abundant 634 
in the brain and is widely distributed throughout the CNS, as well as in various peripheral tissues 635 
(Pertwee et al., 2010). CB2 was identified within peripheral tissues and in glial cells of the brain 636 
(Cabral et al., 2008; Onaivi, 2006).  637 
  CB receptors are found in presynaptic terminals and modulate the release of 638 
neurotransmitters, including glutamate, GABA, glycine, acetylcholine, norepinephrine, dopamine, 639 
serotonin, and cholecystokinin (CCK) (Klee et al., 2012; Lupica et al., 2004). The activation of CB1 640 
and CB2 receptors triggers the inhibition of adenylyl cyclase, voltage-gated Ca2+ channels, and 641 
activation of potassium channels (Onaivi, 2006). These mechanisms are implicated in cannabinoid-642 
evoked inhibition of neurotransmitter release (Fratta and Fattore, 2013). CB receptors also influence 643 
gene expression either directly by activating mitogen-activated protein (MAP) kinase or indirectly 644 
by reducing protein kinase A activity as a consequence of reduced adenylyl cyclase activity (Onaivi 645 
et al., 2002). These mechanisms may explain the different effects of cannabis on working memory, 646 
planning and decision-making, response speed, motor coordination, mood and cognition, as well as 647 
the role of endocannabinoid signaling in various disorders (e.g., anxiety, depression, and addiction)  648 
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(Madras, 2015).  649 
 The processes involved in the release of endocannabinoids, activation of CB receptors, and 650 
their resulting behavioral and psychological effects, are not completely understood. The increased 651 
concentration of intracellular Ca2+ is probably an important cellular trigger, since Ca2+ activates 652 
enzymes involved in endocannabinoid biosynthesis (Robbe et al., 2002). Endocannabinoids 653 
suppress presynaptic glutamate release, leading to a depolarization-induced suppression of 654 
excitation (DSE), and inhibit presynaptic GABA release, leading to depolarization-induced 655 
suppression of inhibition (DSI) (Fratta and Fattore, 2013). Importantly, cannabinoid agonists not 656 
only act via presynaptic CB1 to inhibit the release of glutamate and GABA in the striatum, but also 657 
cause long-term effects on synaptic plasticity (long-term potentiation and depression), that can last 658 
hours or weeks (Hoffman and Lupica, 2001). Fig. 2D depicts some mechanisms associated with 659 
cannabinoid-mediates effects on the CNS. 660 
 661 
7.3. Cannabinoids and zebrafish: neurobehavioral studies  662 
  Although zebrafish has emerged as an efficient model organism in addiction studies 663 
(Stewart et al., 2011), addictive properties of exogenous CB are poorly explored in this species. 664 
Nevertheless, the zebrafish has been claimed to be an appropriate tool to the study CB signaling 665 
because the endocannabinoid system (eCB) has been found extensively conserved between 666 
zebrafish and mammals (Klee et al., 2012). CB1 (Lam et al., 2006; Migliarini and Carnevali, 667 
2009) and CB2 (Elphick, 2012; Rodriguez-Martin et al., 2007) receptors, as well as some 668 
endocannabinoid key enzymes, such as fatty acid amide hydrolase, prostaglandin-endoperoxide 669 
synthase 2, transient receptor potential cation channel 1A, and peroxisome proliferator activated 670 
receptor alpha have homologous funtions and high nucleotide sequence homology when 671 
compared to corresponding human genes (Klee et al., 2012). Although Δ9-THC exposure does not 672 
change the zebrafish behavior in the CPP task (Brock et al., 2017), fish acutely exposed to Δ9-673 
THC exhibit activation of extracellular signal-regulated kinases (ERK) signaling in the lateral 674 
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pallium associated with deficits in spatial memory performance (Ruhl et al., 2014). The zebrafish 675 
eCB system seems modulate associative learning and memory, in which the stimulation of the 676 
CB1 receptor may play a specific role in acquisition and storage of aversive learning and memory, 677 
while CB1 blockade enhances cognitive functions (Ruhl et al., 2015). Moreover, CB1 activation by 678 
Δ9-THC has been found to inhibit acquisition of fear learning, possibly by impairing stimulus 679 
encoding processes in the pallial area of the zebrafish brain (Ruhl et al., 2017).  680 
  Similar to rodents, acute Δ9-THC exposure causes hypolocomotion in zebrafish 681 
(Smirnov and Kiyatkin, 2008; Stewart and Kalueff, 2014), while high Δ9-THC concentrations 682 
impair locomotor activity of zebrafish larvae (Akhtar et al., 2013). THC and CBD treatments alter 683 
synaptic activity at neuromuscular junctions, and fluorescent labeling of primary and secondary 684 
motor neurons reveals a change in branching patterns and a reduction in the number of axonal 685 
branches in the trunk musculature, culminating in reduced heart rates, axial malformations, and 686 
shorter trunks in zebrafish embryos (Ahmed et al., 2018). CBD exposure at blastula increases 687 
developmental dysmorphologies, especially jaw malformation (Carty et al., 2018). CB1 and CB2 688 
double mutant zebrafish have impaired liver development and function (Liu et al., 2016). 689 
Specifically, inhibition of CB receptor activity has been found to disrupt liver development and 690 
metabolic function in zebrafish, affecting hepatic differentiation and liver size due to fewer 691 
hepatocytes and reduced liver-specific gene expression and cell proliferation (Liu et al., 2016). 692 
Moreover, both endocannabinoid system and retinoic acid signaling pathway influence lipid 693 
deposition during zebrafish embryogenesis, with additive function in lipid abundance during 694 
development (Fraher et al., 2015). In general, these data support zebrafish as a useful model to 695 
evaluate the neurobehavioral mechanisms of cannabinoids, as well as the potential involvement of 696 
endocannabinoid system in regulating different biochemical pathways. However, more studies 697 
about the circuit mechanisms underlying eCBs's role in reward, addiction, and anxiety are needed. 698 
 699 
8. Psychedelics 700 
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8.1. General information 701 
Psychedelic drugs are psychoactive substances that affect behavior, consciousness or 702 
thinking, perception, emotion, and other cognitive processes (Belouin and Henningfield, 2018; 703 
Nichols, 2016). Classical tryptamine chemicals-derived, such as lysergic acid (LSD), a well-704 
known hallucinogenic agent, and Ayahuasca, a natural compound used in sacramental beverage 705 
(Johnson et al., 2018; McKenna and Riba, 2015) are examples of psychedelic compounds. In 706 
2013, the National Survey on Drug Use and Health published that more than 24.8 million people 707 
have used LSD at least once in their life.  708 
Psychedelic reactions are subjective, variable, and unpredictable, and the abuse of these 709 
drugs lead to risks to individuals and society (Das et al., 2016). Some users feel positive euphoric 710 
feelings and hallucinogenic sights and sensations, while other report bad feelings including 711 
anxiety, panic, fear, mental confusion, and prolonged psychosis (Carbonaro and Gatch, 2016; Das 712 
et al., 2016; Johnson et al., 2018). Psychedelic drugs can also produce dependence when users 713 
increase drug amount and frequency of consumption, and withdrawal symptoms that include 714 
psychological and physical effects (NIH, 2016). Psychedelic compounds have received interest in 715 
clinical research since classic psychedelics have shown promising effects for treating cancer-716 
related psychological distress, addictions, and depression (Johnson et al., 2018; Tupper et al., 717 
2015).  718 
 719 
8.2. Putative mechanisms of psychedelics in the CNS 720 
  The effects of psychedelic drugs on brain functioning are complex, but LSD and 721 
Ayahuasca, at least in part, share the same mechanism of action. LSD triggers pleiotropic 722 
mechanisms, and its psychosensory effects are mediated by agonism or partial agonism of 723 
serotonergic receptors (5-HT2A mainly, 5-HT1A, 5-HT2C, and 5-HT6) (Halberstadt and Geyer, 724 
2011; Nichols, 2016), as well as via dopaminergic, glutamatergic, and adrenergic modulation (De 725 
Gregorio et al., 2016; Kyzar et al., 2017; Nichols, 2004; Passie et al., 2008). Chronically, LSD 726 
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causes a persistent increase in 5-HT synthesis and turnover, and a downregulation of cortical 727 
5HT2A receptors (Diaz and Huttunen, 1971; Gresch et al., 2005; Lee and Geyer, 1980). 728 
 Ayahuasca preparation is basically composed of N,N-dimethyltryptamine (DMT) plus β-729 
carboline alkaloids (McKenna and Riba, 2018). DMT acts on 5-HT1A, 5-HT2A, and 5-HT2C 730 
serotonin receptors (Dos Santos et al., 2012; Smith et al., 1998), and the agonism of 5-HT2A 731 
receptors also seems to depend on metabotropic glutamate receptors (mGluR) (Gonzalez-Maeso et 732 
al., 2008; Moreno et al., 2011). β-carboline alkaloids have monoamine oxidase-inhibiting 733 
properties, which results in increased brain monoamine levels (e.g., serotonin, dopamine, 734 
norepinephrine) (Dominguez-Clave et al., 2016; Grella et al., 2003). ß-carbolines protect DMT 735 
from degradation in the liver and gut, thus enabling it to cross the blood–brain barrier to exert its 736 
effects on the CNS (McKenna and Towers, 1984). Chronically, Ayahuasca increases the number 737 
of 5-HT receptors localized on platelets (Callaway et al., 1994), expanding the effects triggered by 738 
serotonergic modulation on peripheral tissues. Evolutionarily conserved mechanisms involved in 739 
the effects of psychedelics in the vertebrate brain are summarized in Fig. 2E. 740 
 741 
8.3. Psychedelics and zebrafish: neurobehavioral studies 742 
The use of zebrafish models to explore hallucinogen pharmacology and psychedelic 743 
mechanisms is fairly recent (Kyzar and Kalueff, 2016). Neurochemical and molecular studies 744 
emphasize the growing utility of zebrafish to investigate the role of psychedelics on the 745 
serotonergic neurotransmitter system (Volgin et al. 2019). Chemical manipulations of the 746 
serotonergic neurotransmitter system produce similar behavioral and neuroendocrinological 747 
effects in zebrafish and mammals (Maximino and Herculano, 2010; Maximino et al., 2013). 748 
Serotonergic enzymes, transporters, and receptors, as well as drug effects on 5-HT receptors have 749 
been found evolutionarily conserved in zebrafish (Aldeco et al., 2011; Herculano and Maximino, 750 
2014; Maximino et al., 2015; Norton et al., 2008; Schneider et al., 2012).  751 
The first study characterizing the effects of LSD in zebrafish aimed to explore how LSD 752 
affects stress and behavior (Grossman et al., 2010). LSD (250 µg/L, for 20 min) found increased 753 
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whole-body cortisol levels in zebrafish and also a wide range of behavioral changes induced by 754 
the drug, including increased the time spent in top and lit areas of the test tank, thigmotaxis, 755 
decreased freezing, and impaired shoaling responses (Green et al., 2012; Grossman et al., 2010). 756 
Although lower Ayahuasca concentrations (0.1 and 0.5 ml/L) were found not to affect locomotion 757 
or to reduce anxiety-like behaviors in zebrafish, higher concentrations (1.0 and 3.0 ml/L) reduced 758 
locomotion and triggered anxiety-like behaviors in a concentration-dependent manner (Savoldi et 759 
al., 2017). Importantly, high Ayahuasca concentrations have been found responsible for inducing 760 
locomor deficits and developmental abnormalities in zebrafish embryos, including hatching delay, 761 
loss of equilibrium, edema, and accumulation of red blood cells (Andrade et al., 2018). 762 
Chronically, Ayahuasca has been found to impair discriminative performance and to trigger 763 
locomotor alterations in adult zebrafish (Lobao-Soares et al., 2018). In sum, the zebrafish has 764 
turned out to be a sensitive tool for the analysis of psychedelic drug-induced functional changes in 765 
the vertebrate brain. Although psychedelic drug induced behavioral responses are beginning to be 766 
well characterized in zebrafish, there is a growing need for elucidation of molecular biomarkers of 767 
hallucinogenic action on various neurotransmitter pathways, including serotonin, dopamine, 768 
glutamate, cannabinoid, opioid, and acetylcholine receptors (Neelkantan, 2013), a research area 769 
where zebrafish may be particularly useful in the future. 770 
 771 
9. Concluding remarks 772 
  This review showcased the zebrafish from the perspectives of how this species may be 773 
utilized in studying complex neurobehavioral phenotypes related to drug abuse. The conserved 774 
physiological and molecular mechanisms, as well as the well-characterized behaviors and external 775 
development of zebrafish, make this species a valuable tool with which one can explore drug 776 
abuse related mechanisms (Fontana et al., 2018a; MacRae and Peterson, 2015). Multiple drug 777 
abuse-related phenomena have been explored in zebrafish, which shows a wide range of behaviors 778 
with clinically translatable data. Although addiction research in zebrafish are still on its infancy, 779 
future directions and questions that remain open with regard to the use of the zebrafish in 780 
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modeling drug abuse and addiction-related phenotypes are summarized in Table 4. In sum, a 781 
growing number of studies conducted with zebrafish shows how this species may be utilized in 782 
the analysis of molecular and cellular mechanisms underlying behavioral changes induced by 783 
drugs of abuse. These studies suggest that the zebrafish will have utility in the development of 784 
potential therapeutic strategies for drug abuse related disorders. Furthermore, the often complex 785 
mechanistic nature of these disorders necessitates comprehensive and high throughput essays, 786 
including pharmaceutical compound or mutation screens, approaches that are particularly efficient 787 
with this small and simple vertebrate. Validation of drug abuse-related zebrafish protocols and 788 
characterization of novel zebrafish behaviors will further enhance the utility of this species in 789 
addiction research.  790 
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Fig. 1. Main behavioral tests used to assess drug abuse- and addiction-related phenotypes in 1650 
zebrafish. (A) Novel tank diving task, open field, light-dark test (locomotion, exploration, and 1651 
anxiety-like behaviors); (B) inhibitory avoidance task, conditioned place preference, Y- and T-1652 
maze tests (aversive and spatial memory tasks); (C) social preference task, shoal behavior test 1653 
(seeking for conspecifics and social interaction, respectively); (D) predator test, mirror induced-1654 




Fig. 2. Overview of the main mechanisms triggered by ethanol, opiods, nicotine, cannabinoids, 1657 
LSD, and Ayahuasca on zebrafish CNS. (A) Ethanol directly decreases the brain metabolic 1658 
activity, inhibits glutamatergic neurotransmission, transmembrane flow of Ca2+, and potentiates 1659 
GABA- and glycine-mediated synapses. Indirectly, ethanol activates dopaminergic and 1660 
serotonergic neurons, which innervate the reward system. Ethanol also affects the homeostasis of 1661 
cholinergic, noradrenergic, opioid, endocannabinoid, and purinergic systems. Ethanol 1662 
metabolizing enzymes such as ADH, ALDH, and CYP2E1, as well as CREB-related genes, such 1663 
as NPY, BDNF, ARC, and CRH are modulated by ethanol consumption. These changes are 1664 
involved, at least in part, in biphasic effects, neuroadaptation, and withdrawal symptoms. (B) 1665 
Opioids positively modulate MOP, KOP, DOP opioids receptors, and activate the reward system, 1666 
culminating in the release of dopamine. cAMP dependent biochemical pathways, ion conductance, 1667 
and glutamatergic pathway are also affected by opioids. The endogenous opioid synthesis is 1668 
chronically inhibited by opioid consumption. These actions are involved in the feeling of pleasure 1669 
effects, and dependence. (C) Nicotine activates nAChRs (α2–α10, β2–β4), and promotes the 1670 
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release of neurotransmitters, including acetylcholine, dopamine (reward system), serotonin, 1671 
GABA, glutamate, and norepinephrine in the brain. The activation of nAChRs also increases 1672 
intracellular levels of Ca2+, and modulates both the opioid and endocannabinoid systems. Nicotine 1673 
metabolizing enzymes such as CYP2A, UGT, and FMO, as well as the levels of pCREB, CRF, 1674 
BDNF, and the adenylyl cyclase activity are modulated by nicotine. These changes are involved in 1675 
the nicotine dependence processes. (D) Cannabinoids act on CB1 and CB2 cannabinoids receptors 1676 
and modulate the release of neurotransmitters, including glutamate, GABA, glycine, 1677 
acetylcholine, norepinephrine, dopamine, serotonin, and cholecystokinin. The activation of CB 1678 
receptors triggers the inhibition of adenylyl cyclase, voltage-gated Ca2+ channels, and activation 1679 
of potassium channels, and MAP kinase activity, and endocannabinoids release. These alterations 1680 
are involved in the cannabis effects and addiction. (E) LSD effects are mediated by agonism or 1681 
partial agonism of serotonergic receptors (5-HT2A mainly, 5-HT1A, 5-HT2C, and 5-HT6), as well as 1682 
via dopaminergic, glutamatergic, and adrenergic modulation. Ayahuasca preparation acts on 5-1683 
HT1A, 5-HT2A, and 5-HT2C serotonin receptors, and the agonism of 5-HT2A receptors activates 1684 
metabotropic glutamate receptors. Ayahuasca compounds have monoamine oxidase-inhibiting 1685 
properties, which results in increased brain monoamine levels. Basically, these alterations are 1686 
involved in the effects of thinking and behavior trigger by LSD, and Ayahuasca consumption. 1687 
Abbreviations: Gamma-aminobutyric acid (GABA), neuropeptide Y (NPY), brain derived 1688 
neurotrophic factor (BDNF), activity-regulated cytoskeleton-associated protein (ARC), 1689 
corticotrophin-releasing hormone (CRH), alcohol dehydrogenase (ADH), acetaldehyde 1690 
dehydrogenase (ALDH), cytochrome P450 2E1 (CYP2E1), cyclic adenosine 3′,5′-monophosphate 1691 
(cAMP), cAMP-responsive element-binding protein (CREB), cytochrome P450 2A6 (CYP2A6), 1692 
UDP glucuronosyltransfease (UGT), flavin-containing monooxygenase (FMO), corticotropin 1693 
releasing factor (CRF), mitogen-activated protein (MAP), monoamine oxidase (MAO). Green, red 1694 





Table 1. Main molecular targets of drugs of abuse and homology of corresponding genes between zebrafish and mammalian orthologs. 1698 
  1699 
Drug Gene Encoded protein Main role in drug abuse/addiction Zebrafish orthologs 








aldh2 Aldehyde dehydrogenase 2 Oxidative pathway of alcohol metabolism aldh2a, aldh2b 76.67 & 77.35 87.23 72.79 & 73.67 
bdnf Brain derived neurotrophic factor Ethanol self-administration processes bdnf 78.81 91.77 79.10 
creb1 cAMP responsive element binding protein 1 Genetic predisposition and behavioral effects of ethanol creb1a, creb1b 77.45 & 74.21 95.05 78.51 & 77.09 
crh Adenylyl cyclase Stress-induced alcohol consumption crh 66.02 67.97 70.64 
drd1 Dopamine receptor D1 Reward and reinforcement properties of ethanol drd1 70.99 74.56 69.38 
drd2 Dopamine receptor D2 Alcohol intake, reward and reinforcement effects drd2b, drd2c 76.29 & 78.43 87.92 77.99 & 72.01 
gabra1 Gamma-aminobutiric acid type A1 receptor Consumption and ethanol inhibitory behaviors gabra1 78.08 84.14 77.98 
gabra6 Gamma-aminobutiric acid type A6 receptor Intoxication and withdrawal alcohol symptoms gabra6a 71.45 77.15 68.58 
grin1 Glutamate ionotropic receptor NMDA Excitatory and withdrawal effects of ethanol grin1a, grin1b 78.81 & 92.86 87.19 78.63 & 86.36 
glra1 Glycine receptor alpha1 Ethanol-mediated inhibitory actions glra1 77.29 86.80 77.98 
npy Neuropeptide Y Modulation of ethanol intake and dependence-related processes npy 75.00 80.89 74.86 
th Tyrosine hydroxylase Dopamine-mediated behavior and locomotor effects of ethanol th 100 83.04 67.25 
Opiods 
oprm1 Opioid receptor mu1 Opioid dependence, target of endogenous opioids agents oprm1 77.68 84.70 78.98 
oprk1 Opioid receptor kappa1 Addictive proprieties, endogenous and synthetic opioids ligands oprk1 76.42 73.73 74.36 
oprd1 Opioid receptor delta1 Modulation of opioid reward and addiction oprd1a, oprd1b 73.79 & 76.99 86.70 73.36 & 75.76 
oprl1 Opioid related nociceptin receptor 1 Neurobehavioral responses to opioids oprl1 70.21 84.00 68.39 
Cannabinoids 
cnr1 Cannabinoid receptor 1 Withdrawal and effects of cannabinoids on mood and cognition cnr1 75.53 82.22 75.68 
cnr2 Cannabinoid receptor 2 Reward and psychoactive effects of cannabinoids cnr2 100 79.21 66.06 
faah2 Fatty acid amide hydrolase 2 Endocannabinoid catabolism, cannabis dependence faah2a, faah2b 67.25 & 65.70 70.67 77.05 & 86.36 
ptgs2 Prostaglandin-endoperoxide synthase 2 Involved in endocannabinoid metabolism ptgs2a, ptgs2b 69.47 & 71.60 72.70 70.74 & 72.27 
trpa1 Transient receptor potential cation channel 1A Ionotropic cannabinoid receptor activated by THC trp1a, trpa1b 67.88 & 71.20 80.99 63.97 & 77.57 

















Note: NCBI database was used to assess the nucleotide sequence and to obtain the nucleotide identity rate (%) through blast analyses. 1714 
  1715 












chrna3 Cholinergic receptor nicotinic alpha 3 Nicotine dependence and abstinence, anxiety-like behaviors chrna3 79.08 88.52 76.83 
chrna5 Cholinergic receptor nicotinic alpha 5 Increases nicotine intake, anxiety, and withdrawal chrna5 71.59 84.16 70.97 
chrna6 Cholinergic receptor nicotinic alpha 6 Increases risk of nicotine dependence, withdrawal symptoms chrna6 73.76 81.01 74.70 
chrna7 Cholinergic receptor nicotinic alpha 7 Nicotine-stimulated dopamine release, abstinence chrna7 72.11 87.58 71.92 
chrnb2 Cholinergic receptor nicotinic beta 2 Nicotine self-administration and conditioning reinforcement chrnb2 80.32 81.90 79.98 
chrnb4 Cholinergic receptor nicotinic beta 4 Nicotine dose-dependent tolerance development chrnb4 79.57 83.05 76.53 
Psychedelics 
htr1a 5-hydroxytryptamine receptor 1A Stimulant effects, self-boundaries and cognitive control htr1aa, htr1ab 70.88 & 67.60 81.58 77.35 & 67.57 
htr2a 5-hydroxytryptamine receptor 2A Development of tolerance, facilitates dopamine neurotransmission htr2a 67.31 87.12 71.48 
htr2c 5-hydroxytryptamine receptor 2C Self-administration, addictive effects of hallucinogens htr2cl1 69.67 83.25 69.23 
mao a Monoamine oxidase A Psychedelic monoamine-oxidase-inhibiting properties mao 69.95 81.10 69.87 
tph1 Tryptophan hydroxylase 1 Biosynthesis of serotonin, hyper serotonergic activity tph1a, tph1b 71.43 & 71.69 84.12 73.31 & 71.55 
        Mean 77.02 82.63 76.00 
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Table 2. Overview of main behavioral tests and endpoints used to evaluate the effects of drugs of abuse and addiction behavior in adult zebrafish. 1716 
 1717 
 1718 
  1719 
Behavioral test Major endpoints References 
Novel tank diving task 
Locomotor parameters: Distance traveled, Absolute turn angle, Maximum speed, Immobility. Anxiolytic-like 
behavior: ↑ Time spent in the top area, ↑Transitions to the top area, ↓Latency to enter the top area. Anxiogenic-like 
behavior: ↑Time spent in bottom area, ↑Freezing/Erratic movements. 
Egan et al., 2009; Gerlai et al., 2000; Rosemberg et al., 2011; 
Stewart et al., 2014; Tran et al., 2016 
Open field Thigmotaxis behavior: Entries to the center area, Time in the center area, Entries to periphery area, Time in the periphery area. Exploratory behavior:  Distance traveled, Maximum speed, Time immobile. 
Baiamonte et al., 2016; Champagne et al., 2010;  
Grossman et al., 2010; Nema et al., 2018 
Light-dark test Anxiolytic-like behavior: ↑Time spent in the lit area. Anxiogenic-like behavior: ↑Time spent in the dark area, ↑Freezing, ↑Risk assessment episodes. 
Chaves et al., 2018; Facciol et al., 2019; Holcombe et al., 2014; 
Maximino et al., 2010 
Inhibitory avoidance task Aversive memory: Latency to enter in the aversive stimulus area. Time in the aversive stimulus area. Blank et al., 2009; Manuel et al., 2014; Nazario et al., 2015;  Cleal and Parker, 2018. 
Conditioned place preference Drug-seeking behavior: Preference for the drug-associated compartment. Brock et al., 2017; Collier et al., 2014; Mathur et al., 2011 
Y- and T-maze tests Spatial memory and visual discrimination learning:  Total arm entries, Time spent in each arm, Center entries, Freezing, Directional preference, Frequency of choice, Repetitive alternation. Aoki et al., 2015; Cognato et al., 2012; Grossman et al., 2010 
Social preference task Seeking for conspecifics:  Time spent near the conspecific area, Transitions to the conspecific area.. Baggio et al., 2018; Fontana et al., 2018;  Grossman et al., 2010 
Shoal behavior test Shoaling  behavior:  Inter-fish distance,  Nearest neighbor distance,  Farthest neighbor distance,  Shoal area.  Anxiolytic-like behavior:  Shoaling disruption.  Anxiogenic-like behavior: ↑Shoal cohesion. 
Fontana et al., 2018;  Müller et al., 2017;  Canzian et al. 2017;  
Fernandes et al., 2015 
Predator test Avoidance and fear-like responses:  Time in the predator area, Transitions to the predator area, Freezing episodes, Risk assessment episodes. Gerlai et al., 2000;  Fontana et al., 2018;  Ladu et al., 2015 
Mirror-induced aggression test Aggressive-like behavior:  Time in the mirror area, Transitions to the mirror area, Aggressive episodes, Duration of aggressive episodes. Echevarria et al., 2011;  Fontana et al., 2016; Gerlai et al., 2000 
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Table 3. Overview of the main experimental protocols for modeling drug abuse and addiction-related behaviors in zebrafish. 1720 
Drug Experimental protocol Biological response References 
Ethanol 
Acute etanol exposure 
(0.25, 0.5, 1.0% v/v for 1 h) 
U-shaped response. Ethanol modulates locomotor-, aggression-, anxiety-, and fear-like 
behaviors. Increase brain alcohol levels, trigger oxidative stress and neurochemical changes. 
Gerlai et al., 2000; Rosemberg et al., 2012; Fontana et al., 2016; 
Chatterjee and Gerlai, 2009; Chatterjee, Shams and Gerlai, 2014 
Ethanol conditioned place preference 
(1.5% v/v for 20 min) Increases alcohol preference, measures positive-reinforcing qualities of alcohol. Mathur and Guo 2011; Mathur, Lau, and Guo, 2011 
Intermittent ethanol exposure 
(1.0 % v/v, 20 min per day, for 8 
consecutive days) 
Elicits defensive responses by stimulating social behavior, geotaxis, and scototaxis, which 
reflect anxiogenesis. Induces tolerance and withdrawal effects and trigger oxidative stress. Mathur and Guo, 2011; Müller et al., 2017 
Continuous ethanol exposure 
(0.5% v/v applied continuously for 10 
weeks) 
Tolerance and withdrawal effects. Ethanol triggers anxiety-like responses, and impairs 
aversive learning. Changes in neurochemicals levels and oxidative stress are observed. 
Damodaran et al., 2006; Dlugos and Rabin, 2003; Egan et al., 
2009; Gerlai et al., 2009; Agostini et al., 2018; Chaves et al., 
2018; Cachat et al., 2010 
Voluntary ethanol intake 
(10% or 20% ethanol (v/v) mixed with 
gelatin) 
Stimulatory effects on locomotion, reduces anxiety, potentiates aggressive behaviors, and 
increases the expression of galanin and orexin in specific hypothalamic areas. Sterling et al., 2015 
Fetal alcohol spectrum disorder 
(0.12% ethanol from 2 to 9 dpf) 
Behavioral deficits in social conduct and anxiety-like responses. Cognition, learning, and 
memory are altered. Neurochemical changes and teratogenic ethanol effects are observed. 
Parker et al., 2014; Fernandes et al., 2019; Lutte et al., 2018; 
Amorim et al., 2017; Cleal and Parker, 2018; Baggio et al., 2018; 
Fernandes et al., 2018; Ramlan et al., 2017 
Opioids 
Acute diacetylmorphine exposure 
(15 and 25 mg/L,  for 20 min) Evokes hyperlocomotion without changing anxiety-like behaviors. Stewart and Kalueff, 2014 
Morphine acute exposure 
(2.0 mg/L, for 15 min) 
Elicits anxiolysis in zebrafish by decreasing erratic movements and increasing the time in the 
top area of the tank. Taylor et al., 2017 
Morphine conditioned preference 
paradigm 
(1 mg/mL, for 30 min) 
Conditioned morphine preference is increased, which is blocked by naloxone (an opioid 
antagonist) and dopaminergic antagonists. Lau et al., 2006; Wong et al., 2010 
Morphine larval exposure 
(0.4, 0.8, and 1.5 µM, for 1 h) 
Exposure modulates the choice preference and such response is attenuated by opioid and 
dopamine antagonists Bretaud et al., 2007 
Self-administration of hydrocodone 
hydrochloride  
(1.5 μg of hydrocodone from a solution of 
6mg/L ) 
Robust self-administration of hydrocodone hydrochloride, which is mu-opioid receptor-
dependent and is blocked by dopaminergic and glutamatergic antagonists Bossé and Peterson, 2017 
Morphine withdrawal 
(1.5 mg/L, for 2 weeks) Evokes anxiogenesis and changes in whole-body cortisol levels Cachat et al., 2010 
  1721 
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Drug Experimental protocol Biological response References 
Nicotine 
Acute nicotine exposure 
(4 or 8 mg/L, for 3 min) 
Anxiolysis, reduces shoal cohesion and swimming speed of zebrafish. 
Improves aversive and spatial memories, and is related to changes in cholinergic and 
dopaminergic signaling. 
Ziani et al., 2018; Miller et al., 2013; Braida et al., 2014; May et 
al., 2016; Levin and Chen et al., 2004; Eddins et al., 2009 
 
Chronic nicotine exposure 
(1-2mg/L, for 4 days) Increases shoaling and facilitates anxiogenic responses. Stewart et al., 2015; File et al., 2000 
Nicotine conditioned place paradigm 
(15 mg/L, 20 min per day, for 14 days) 
Dose-dependent acute nicotine reinforcement response that persists following 3 weeks of 
abstinence. Failacce et al., 2018 
Nicotine embryo exposure 
( 5, 10, or 20 mg/L, for 10 days) Changes the notochord length, reduces eye diameter, alters behavior and decreases survival Parker and Conhaughton, 2007 
Cannabinoids 
Acute exposure to Δ9-
tetrahydrocannabinol 
(100 nM, for 1h) 
Triggers hypolocomotion. Extracellular signal-regulated kinases signaling activation and 
deficits in spatial memory performance and associative learning are observed. 
Ruhl et al., 2014; Ruhl et al., 2015; Ruhl et al., 2017; Stewart and 
Kalueff, 2014; Smirnov and Kiyatkin, 2008 
 
Δ9-tetrahydrocannabinol 
and canabidiol embryo exposure 
(2, 4, 6, 8 and 10 mg/L of Δ9-THC, and 1, 
2, 3 and 4 mg/L of CB, from 5.45-48 hpf) 
Δ9-THC impairs locomotor activity of larvae. Δ9-THC and CB treatments reduce the number 
of axonal branches in the trunk musculature, culminating in reduced heart rates, axial 
malformations, and shorter trunks in embryos. 
Akhtar et al., 2013; Ahmed et al., 2018; Carty et al., 2018 
Psychedelics 
Acute lysergic acid exposure 
(250 µg/L, for 20 min) 
Increases whole-body cortisol levels and induces behavioral changes, such as increases the 
time in top and lit areas, thigmotaxis, decreases freezing, and impairs shoaling responses. Green et al., 2012; Grossman et al., 2010 
Acute Ayahuasca exposure 
(0.1, 0.5, 1.0, and 3.0 ml/L, 1 h) 
Higher concentrations (1.0 and 3.0 ml/L) reduce locomotion and trigger anxiogenic-like 
behaviors in a concentration-dependent manner. Savoldi et al., 2017 
Ayahuasca embryo exposure 
(0.064; 0.3; 1.6; 8; 40; 106 200 and 1000 
mg/L, for 96 h) 
High Ayahuasca concentrations causes locomotor deficits and developmental abnormalities, 
including hatching delay, loss of equilibrium, edema, and accumulation of red blood cells. Andrade et al., 2018 
Chronic Ayahuasca exposure 
0.1 and 0.5 ml/L, for 13 days Impairs discriminative learning performance and causes locomotor changes in adults. Lobao-Soares et al., 2018 
 1722 
* The experimental exposure protocols may vary according to the study. Abbreviations: Δ9-tetrahydrocannabinol (Δ9-THC), canabidiol (CB). 1723 
  1724 
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Table 4. Selected open questions in the field of zebrafish modeling drug abuse and addiction. 1725 
Questions 
• Can zebrafish help elucidate unknown molecular pathways evolutionarily conserved involved 
in addiction? 
• Can zebrafish serve as a suitable tool to identify novel therapeutic targets and pharmacological 
treatments against drug addiction? 
• Can novel drug abuse- and addiction-related behavioral phenotypes still be validated in 
zebrafish models? 
• Can comorbidities associated with drug abuse and addiction be studied in zebrafish? 
• Can zebrafish help investigate the role of external factors (e.g., depression, social deprivation, 
and individual susceptibility) in drug addiction models? 
• Can anti-addiction drugs treat addiction-related symptoms in zebrafish? 
• Are epigenetic processes involved in drug abuse and addiction in zebrafish? 
• Do sex differences play a key role in drug abuse and addiction in zebrafish models? 
• Are there any genetic, biochemical, and behavioral differences among zebrafish strains 
that contribute to drug addiction response? 
• Can duplicated genes be differently modulated after drug exposure, playing a role in the 
effects of drug abuse and addiction? 
 1726 
 1727 
 1728 
 1729 
 1730 
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